Overview of Requip-Modutab

What is Requip-Modutab? (Overview)

Property	Description
Active ingredient	Ropinirole (as hydrochloride salt)
Form	Prolonged-release tablets (modified-release)
Pharmacological class	Dopamine Agonist (Non-ergoline derivative)
Common use	Addressing motor disturbances related to dopamine deficiency
Origin	Synthetic compound

Requip-Modutab is a synthetic, prescription-only medication whose active component, Ropinirole, belongs to the pharmacological class of Dopamine Agonists. Ropinirole is classified as a non-ergoline derivative with a distinct receptor binding profile compared to older agents. This drug's function is centralized in the nervous system, acting by directly stimulating receptors and substituting for the body's deficient supply of natural signaling molecules. This precise therapeutic classification is clinically recognized for its role in managing neurological conditions related to motor control.

The product is a single-component medication containing Ropinirole hydrochloride, presented in the specific form of a prolonged-release tablet for oral administration. This extended-release formulation is the distinguishing characteristic of the Modutab presentation; it is specifically engineered to release the active ingredient slowly and steadily over many hours. This controlled-release system ensures a consistent level of Ropinirole in the bloodstream, a desirable pharmacokinetic feature that minimizes fluctuation between doses.

The general purpose of Ropinirole is to help restore necessary neurological balance by mimicking the function of dopamine, a vital brain chemical that regulates movement. The active ingredient functions as an agonist, meaning it specifically binds to and activates certain dopamine receptor subtypes (D2 and D3) in the brain. This mechanism ultimately helps to stabilize the signals required for coordinated and smooth muscle function, offering a foundational approach to mitigating motor disturbances.

What side effects are possible with Requip-Modutab?

Possible Side Effects and Safety Information

The safety profile of Ropinirole (Requip-Modutab) is categorized by government regulatory agencies based on the observed frequency and system-organ class of adverse reactions documented in clinical use.

Documented Frequency Classifications

Side effects are often grouped by their incidence rate, consistent with official regulatory classification:

Very Common (more than 1 in 10 patients): Nausea, Somnolence (Drowsiness), and Dyskinesia (involuntary movements, particularly in Parkinson's Disease).
Common (up to 1 in 10 patients): Vomiting, Dizziness, Hallucinations, Constipation, Fatigue, and Peripheral edema (swelling).
Uncommon (up to 1 in 100 patients): Syncope (fainting), Orthostatic Hypotension (postural dizziness), and Psychotic reactions (e.g., delusions or paranoia).

Key Safety Domains and Serious Adverse Reactions

Adverse reactions primarily affect the Nervous System and Psychiatric disorders classes. Certain effects are designated as serious due to their potential impact, including the manifestation of Impulse Control Disorders (ICDs), such as pathological gambling, hypersexuality, or compulsive spending. A further safety consideration is the risk of sudden onset of sleep (sleep attack), which may occur without prior warning.

Contextual and Population Safety Notes

Certain adverse reactions, such as nausea, vomiting, and somnolence, are most frequently reported during the initial phase of treatment and the period of dose escalation. Conversely, the occurrence of dyskinesia is a safety note associated with long-term exposure in the management of Parkinson’s Disease. Official documents also note that the frequency of adverse events, particularly hallucinations, may be higher in older adults (65 years and older). Regulatory restrictions include contraindications for individuals with known hypersensitivity to Ropinirole and those with severe hepatic impairment (liver problems).

Overdose and Emergency Response

An overdose of Requip-Modutab (Ropinirole prolonged-release) is officially documented to cause manifestations related to excessive dopaminergic activity, primarily affecting the central nervous system and the cardiovascular system.

Overdose scope

Feature	Official Regulatory Statement
Documented overdose presentations	Severe nausea, vomiting, confusion, drowsiness (somnolence), hallucinations, dizziness, fainting (syncope), and uncontrolled body movements (dyskinesia).
Physiological systems affected	CNS and Cardiovascular System, resulting in effects like tachycardia, bradycardia, orthostatic hypotension, and potentially seizure or transient sinus arrest.
Dose-related or exposure-related factors	Breaking, crushing, or chewing the prolonged-release tablets may lead to an overdose, as the medicine is released into the body too quickly.
Emergency-response statements	Contact a physician or hospital emergency room immediately; bring the medicine package.
When immediate medical help is required	Immediately seek emergency medical attention if severe manifestations such as collapse, seizure, or trouble breathing occur.

Official Overdose Statements

Mandatory Urgent Action: Immediate emergency medical attention must be sought for any severe symptoms, or if the individual cannot be awakened.
Management Focus: There is no specific antidote documented in regulatory information; treatment is restricted to symptomatic and supportive care.
Monitoring: Hospitalization and continuous cardiac monitoring are required for a sufficient period to observe and maintain cardiovascular stability.
Population Note: Older patients may exhibit increased sensitivity to the central nervous system effects of overdose, such as confusion.

The regulatory guidance defines the overdose profile by documenting the severe CNS and cardiovascular risks, which necessitate an immediate call for professional medical intervention upon the onset of specific, life-threatening symptoms.

Therapeutic Uses of Requip-Modutab

What Requip-Modutab Treats: Main Uses and Benefits

Requip-Modutab is commonly used to help with symptoms falling under two primary therapeutic domains: the core motor difficulties of Parkinson's Disease and the sensory and motor distress of moderate to severe primary Restless Legs Syndrome (RLS). This is relevant for easing symptoms that interfere with daily comfort and stability. In these situations involving certain distressing symptoms, the treatment is applied in addressing symptom clusters like bradykinesia (slowness of movement), muscle rigidity, the resting tremor, and the irresistible urge to move the legs.

This supportive approach contributes to improved comfort and assists with maintaining functional stability for patients dealing with these conditions. It contributes to easing the overall symptom load and supports general well-being during symptomatic phases, particularly for those whose symptoms escalate or become more noticeable at night. This is relevant in contexts involving heightened systemic burden.

Quick Fact: Relief for Nocturnal Sensory Distress and Impaired Voluntary Motor Control.

Eligibility and Restrictions for Use

Who Can and Cannot Use Requip-Modutab?

Eligibility for Requip-Modutab (ropinirole modified-release) is strictly defined by official regulatory labeling, setting clear rules on who is permitted to use the medicine and who must not.

Contraindicated Populations (Must Not Use)

Classification	Population/Condition
Absolute Prohibition	Patients with known hypersensitivity or allergic reaction to Ropinirole or any excipient.
Organ Dysfunction	Patients with severe hepatic impairment or severe renal impairment (creatinine clearance <30 mL/min) who are not on regular hemodialysis.
Metabolic Risk	Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.

Restricted and Non-Recommended Use

Use is not recommended for children and adolescents below 18 years of age, as the safety and effectiveness have not been established in the pediatric population.

For pregnancy, use is conditional and generally not recommended unless the potential benefit outweighs the risk to the fetus. Similarly, use is not recommended during breastfeeding due to the potential to inhibit lactation.

Conditional use with caution is required for patients with severe cardiovascular disease and those with a history of major psychiatric or psychotic disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes Ropinirole's interaction profile primarily through its effect on metabolism and its receptor activity. The drug is mainly cleared via the CYP1A2 enzyme. Co-administration with CYP1A2 inhibitors, such as Fluvoxamine or Ciprofloxacin, may reduce the clearance of Ropinirole, resulting in higher plasma concentrations. Conversely, starting or stopping high-dose estrogen therapy, such as in HRT, is also officially noted to reduce oral clearance.

Documented Pharmacodynamic Effects

Interacting Substance Category	Regulatory Statement on Interaction Outcome
Dopamine Antagonists (e.g., Antipsychotics, Metoclopramide)	May diminish the effectiveness of Ropinirole due to opposing pharmacological actions at dopamine receptors.
CNS Depressants and Alcohol	May increase the risk of somnolence or falling asleep during daily activities.

Co-administration with L-dopa (Levodopa) is documented to slightly increase the maximum concentration of L-dopa but does not affect Ropinirole's own drug levels. Ropinirole may be taken with or without food, as a high-fat meal does not affect the overall extent of absorption. The official prescribing information notes that drug elimination is expected to be reduced in hepatically impaired patients, which may lead to higher plasma levels.

Mechanism of Action

Targeting Dopamine D2 and D3 Receptors

Requip-Modutab (ropinirole) works by acting as a non-ergoline dopamine agonist, meaning it binds to and directly stimulates the post-synaptic D2 and D3 dopamine receptors in the brain, functionally stimulating target receptors, thereby modulating signaling typically mediated by endogenous dopamine. This binding initiates a specific G-protein inhibitory cascade within neurons, which alters the balance of signals necessary for motor control.

Modulating the Central Motor Pathway

The primary site of action is the nigrostriatal pathway of the central nervous system, which is essential for regulating coordinated movement. By stimulating dopamine receptors within the basal ganglia motor circuit, the drug modifies dysregulated signaling patterns within the circuit. This targeted modulation influences downstream activity, leading to alterations in muscle tone and movement initiation patterns.

️ Dual Central and Peripheral Effects

While the main effect is central, the mechanism also involves peripheral D2 receptors, resulting in non-motor physiological consequences. The drug influences the body's neuroendocrine regulation by suppressing prolactin release and can modulate peripheral vascular tone, which sometimes results in a decrease in blood pressure upon standing.

Dosage and Administration Information

How to Use Requip-Modutab

Requip-Modutab (ropinirole prolonged-release) is administered orally in the form of an extended-release tablet designed for once-daily intake. To maintain the intended controlled release of the active substance, the tablets must be swallowed whole and not be chewed, crushed, or divided. The medication may be taken with or without food, but should be taken consistently at approximately the same time each day.

Dosing and Titration Principles

Clinical usage typically begins with a titration phase involving gradual dose increases. The initial adult dose for Parkinson's Disease treatment is 2 mg once daily for the first week. The dose is subsequently increased by 2 mg at weekly intervals or longer, based on the required effect, until the appropriate maintenance dose is achieved. The highest daily amount described for this indication is 24 mg.

Procedural Administration

If a transition from the immediate-release form to the prolonged-release tablet is required, the new daily dose should be chosen to match the total previous daily dose. Conversely, when treatment is to be discontinued, the dose should be gradually tapered over a seven-day period. For specific populations, such as patients with end-stage renal disease receiving maintenance hemodialysis, the maximum permissible daily dose is reduced to 18 mg. The medication is not recommended for use in children under 18 years of age.

Recent Clinical Evidence

Requip-Modutab: Recent Clinical Evidence

Overview of Research Findings

This section summarizes research that has explored the measured effects of Requip-Modutab (ropinirole prolonged-release) in studies involving Parkinson's disease (PD). These studies explored the effects on measured patient outcomes and symptom levels.

Research evaluated the primary endpoints of motor function scores and quality of life measures in individuals with PD who received Requip-Modutab.

Key Studies and Outcomes

Efficacy Studies

Studies evaluated the primary data collected on Requip-Modutab at various doses. One randomized controlled trial compared the measured change in primary symptoms (such as rigidity and tremor) between the study group receiving the drug and the study group receiving the placebo.

Combination Therapy Research

One study explored whether combining Requip-Modutab with levodopa affected the overall measured outcomes. Fewer studies have specifically evaluated the effects of Ropinirole when used alongside other common PD treatments.

Safety and Long-term Data

Side Effect Profile

Side Effect Profile: Study data described the observed side effects. The data indicated that the most commonly reported events during the studies included nausea, dizziness, and somnolence (drowsiness).

Long-term use

Long-term use: Research examined the data on individuals with PD over extended periods, and evaluated whether there were measurable changes in the condition's progression.

Overall Summary of Evidence

Research has been conducted to examine the measured effects of Requip-Modutab on Parkinson's disease.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Requip-Modutab (FAQ)

Q: How does the 'Modutab' part change how the drug works compared to regular Requip?

The 'Modutab' designation means the tablet uses a prolonged-release or extended-release formulation. This is engineered to release the active ingredient, ropinirole, slowly over a 24-hour period. This mechanism allows the medication to be taken once daily and helps maintain more consistent levels of the drug in the bloodstream compared to the immediate-release version.

Q: Can Requip-Modutab be used for restless legs syndrome (RLS) as well as Parkinson's?

According to the official product information, Requip-Modutab (ropinirole extended-release tablets) is officially indicated only for the treatment of Parkinson's disease. While the immediate-release form of ropinirole is indicated for RLS, the prolonged-release version is not indicated for this condition.

Q: How quickly should I expect to notice a difference after starting Requip-Modutab?

The official clinical use involves a titration process where the dose is increased gradually over several weeks. Since the appropriate dose is found by assessing individual therapeutic response over this period, there is no set timeline for when a patient may notice a specific difference in symptoms.

Q: Is it normal to feel dizzy or lightheaded when first taking Requip-Modutab?

Official information indicates that dizziness is a very common side effect. Feeling lightheaded or fainting may also occur, especially when starting the medication or increasing the dose. Regulatory warnings indicate that lightheadedness or dizziness can be related to orthostatic hypotension (a drop in blood pressure when standing).

Q: Can taking Requip-Modutab affect my blood pressure?

Yes, official safety information indicates that this medication can affect blood pressure. It may cause hypotension (low blood pressure), including a drop upon standing (orthostatic hypotension). It may also be associated with an elevation of blood pressure and changes in heart rate.

Q: Does smoking affect how Requip-Modutab is absorbed or works?

Yes. Ropinirole is broken down primarily by the CYP1A2 enzyme in the liver. Since smoking can change the activity of this enzyme, it may alter how the drug is cleared from the body. Changes in smoking habits should be discussed with a healthcare professional, as they may require a review of the medication.

Q: What is the difference between ropinirole and pramipexole (Mirapex) for Parkinson's?

Both ropinirole and pramipexole are classified as non-ergoline dopamine agonists used to treat Parkinson's disease. Ropinirole works primarily by stimulating the D2 and D3 receptor subtypes. While both share a similar mechanism, differences in chemical structure and specific receptor binding exist. The full details are available in their respective official product information.

Q: Does this drug affect driving ability, and if so, how?

Yes, the drug may affect driving ability. It can cause somnolence (drowsiness), and some patients have reported falling asleep without warning while engaged in daily activities. Official labeling contains a warning regarding this risk.

Q: Can I drink coffee or caffeine while taking Requip-Modutab?

While caffeine is not explicitly named as a prohibited substance, the drug is metabolized by the CYP1A2 enzyme. Since caffeine can affect this enzyme, there is a potential for interaction that could alter the drug's levels in the body. Questions regarding this potential interaction are best addressed by a healthcare provider.

Q: Is the risk of side effects higher when first starting Requip-Modutab?

According to official adverse reaction data, side effects such as nausea, vomiting, and somnolence (drowsiness) are reported most frequently during the initial phase of treatment and the period when the dose is being gradually increased.

Q: Does Requip-Modutab have any known interaction with alcohol?

Yes. The drug label advises that taking Requip-Modutab with other sedating medications, including alcohol, may increase the risk of somnolence (drowsiness) or sudden sleep while engaged in daily activities.

Q: Are there any long-term effects of taking Requip-Modutab?

Official information indicates that continued use in the management of Parkinson’s disease is associated with certain effects. Long-term exposure carries a risk of developing Dyskinesia (involuntary movements) and the manifestation of Impulse Control Disorders (ICDs).

Q: Are weight changes a common side effect of Requip-Modutab?

While significant or common weight changes are not listed as very frequent side effects, clinical trial data has reported both weight loss and weight gain as less common adverse reactions in some patients.

Q: What non-prescription medicines or supplements should I check for interactions with Requip-Modutab?

Any non-prescription product known to significantly affect the CYP1A2 enzyme, which is responsible for breaking down ropinirole, should be reviewed. Regulatory information indicates that potential interactions are best reviewed by a healthcare professional.

Q: Is it safe to take Requip-Modutab with common pain relievers like ibuprofen?

Specific, common pain relievers like ibuprofen are not listed as having a major or contraindicating interaction in the official drug label. Information regarding all over-the-counter medications and supplements is best reviewed by a healthcare professional.

Q: What happens if I forget to take my Requip-Modutab dose?

Patient information generally instructs that if a dose is missed, the patient should not take an extra dose to compensate. Taking an extra dose may increase the risk of side effects, and if treatment is stopped for several days, the dose may need to be retitrated.

Q: Are there generic versions of Requip-Modutab available?

Yes, generic versions of the active ingredient, ropinirole extended-release tablets, are available for prescription in the market.

Q: Is a metallic taste in the mouth reported with Requip-Modutab?

A metallic taste is not commonly listed as an adverse reaction in the key safety sections of official drug labels. Common taste-related issues are not frequently documented.

Q: Does Requip-Modutab interfere with sleep patterns?

Yes, official safety information indicates interference with sleep. Common effects include somnolence (drowsiness) and the risk of sudden sleep attacks. Additionally, less common side effects such as abnormal dreams may suggest a general disturbance in sleep patterns.

Q: What vision changes might be connected to taking Requip-Modutab?

Regulatory documents have reported vision-related effects as less common or rare side effects. These include blurred vision, double vision, and general visual disturbances. Official labeling notes that significant changes in vision should be discussed with a healthcare professional.

Q: Is it normal if I sometimes see the tablet shell in my stool?

Yes, official product information explains that this may be normal. The extended-release tablet is manufactured with a protective outer shell that is not absorbed by the body. This empty, non-dissolving shell may occasionally be seen in the stool, but this does not mean the medication was not absorbed.

Q: How long does it take for Requip-Modutab to be completely out of the system?

The half-life of ropinirole is approximately 6 hours in patients. The half-life is the time it takes for half the drug to be eliminated. While complete elimination takes several half-lives, steady-state concentration is typically achieved within about two days of consistent dosing.

Q: Are there any dietary restrictions while using Requip-Modutab?

No specific dietary restrictions are required. The official prescribing information states that the medication can be taken with or without food. Taking it with food may sometimes help reduce the incidence of nausea.

Q: What should I tell my dentist or surgeon before a procedure if I take Requip-Modutab?

Official warnings recommend that healthcare professionals are informed about this medication prior to medical procedures. Requip-Modutab may enhance the effects of Central Nervous System (CNS) depressants, including certain anesthetics or sedatives commonly used, which could increase the risk of excessive drowsiness.

Q: Do other medications for Parkinson's disease interact with Requip-Modutab?

Yes. The drug is often used alongside levodopa (L-dopa), and the combination is well-documented. Additionally, regulatory documents warn that dopamine antagonists (a class of drugs that includes certain medications for nausea and psychiatric conditions) may reduce the effectiveness of ropinirole.

Q: Why is the 'Modutab' version often preferred for later stages of the condition?

The 'Modutab' or prolonged-release version provides more consistent drug levels over 24 hours. This smooth drug delivery is often a key therapeutic goal in the management of advanced Parkinson's disease to help minimize motor fluctuations between doses.

Q: Is Requip-Modutab a controlled substance?

No, the active ingredient, ropinirole, in its extended-release tablet form is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA).

How should Requip-Modutab be stored and disposed of?

Official Storage and Disposal Requirements

This information is based strictly on regulatory product labeling for Requip-Modutab (ropinirole prolonged-release tablets).

Mandatory Storage Conditions

Requirement	Official Statement
Temperature	Do not store above 25 C (Store at room temperature).
Protection	Store in the original package to protect from light and moisture.
Child Safety	Keep out of the sight and reach of children.
Handling	Tablets must be swallowed whole and must not be chewed, crushed, or divided.

Disposal Instructions

To protect the environment, unused or expired Requip-Modutab should not be thrown away via wastewater or household waste. Disposal must be performed in accordance with local requirements, such as returning the medicine to a pharmacist or an authorized collection point.

Requip-Modutab